Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Haebe, MD, Veit Bücklein, MD, Heidrun Drolle, Ulf Schoenermarck, Wolfgang Hiddemann, PhD, Michael von Bergwelt, Johanna Tischer, MD

Blood (2019) 134 (Supplement_1): 1982.

https://doi.org/10.1182/blood-2019-130685

Published: 2019

Journal Articles

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Elena Häbe, Veit Bücklein, MD, Christoph Schulz, MD, Heidrun Drolle, Susanne Fritsch, Georg Ledderose, Michael von Bergwelt, MD, Wolfgang Hiddemann, PhD, Johanna Tischer

Blood (2018) 132 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2018-99-119103

Published: 2018

Journal Articles

Clonal Evolution of Relapsed CBFB/MYH11 Rearranged Acute Myeloid Leukemia (AML)

Sabrina Opatz, MD, Sebastian Vosberg, Bianka Ksienzyk, Sebastian Tschuri, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, Dr., Stephanie Schneider, PhD, Martin Neumann, Claudia D. Baldus, MD, Christian Thiede, MD, Jan Moritz Middeke, MD, Friedrich Stoelzel, Stefan K. Bohlander, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, PhD, Klaus H. Metzeler, MD, Philipp A. Greif, MD PD

Blood (2018) 132 (Supplement 1): 2772.

https://doi.org/10.1182/blood-2018-99-115881

Published: 2018

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Costimulatory Expression Profiling of AML Blasts Identifies Surface Markers with High Correlation to Isolated NPM1 Mutation

Felix S Lichtenegger, MD, Michael Krempasky, Karsten Spiekermann, MD, Jan Braess, MD, Wolfgang Hiddemann, PhD, Marion Subklewe, MD

Blood (2011) 118 (21): 2511.

https://doi.org/10.1182/blood.V118.21.2511.2511

Published: 2011

Journal Articles

Composition of PBMC Population and Functionality of T- and NK-Cells in AML Patients Receiving Cytotoxic Maintenance Therapy,

Felix S Lichtenegger, MD, Robin Lorenz, Patrick Palluch, Ulrich Hoffmueller, MBA, PhD, Jan Braess, MD, Wolfgang Hiddemann, PhD, Barbara Beck, PhD, Marion Subklewe, MD

Blood (2011) 118 (21): 3601.

https://doi.org/10.1182/blood.V118.21.3601.3601

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy

Felix S Lichtenegger, MD, Katharina Mueller, Wolfgang Hiddemann, PhD, Dolores J Schendel, Marion Subklewe, MD

Blood (2011) 118 (21): 358.

https://doi.org/10.1182/blood.V118.21.358.358

Published: 2011

Journal Articles

A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia

Thomas Köhnke, MD, Daniela Sauter, MD, Katharina Ringel, Jan Braess, MD, Wolfgang Hiddemann, PhD, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2011) 118 (21): 934.

https://doi.org/10.1182/blood.V118.21.934.934

Published: 2011

Journal Articles

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Blood (2011) 118 (21): 782.

https://doi.org/10.1182/blood.V118.21.782.782

Published: 2011

Journal Articles

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, Dr., Michael Unterhalt, Dr., Bernd Metzner, Michael Pfreundschuh, MD, Peter Staib, Georg Jacobs, Hans Walter Lindemann, Wolf-Dieter Ludwig, H. Tilman Steinmetz, Lorenz Truemper, Hannes Wandt, Christian Buske, Martin H. Dreyling, PhD, Wolfgang Hiddemann, PhD

Blood (2011) 118 (21): 1639.

https://doi.org/10.1182/blood.V118.21.1639.1639

Published: 2011

Journal Articles

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, PhD, Roswitha Forstpointner, PhD, Martin Dreyling, PhD, Martin Gramatzki, PhD, Hans-Peter Böck, MD, Mathias Hänel, MD, John Seymour, MD, Manfred Planker, MD, Ulrich Dührsen, PhD, Klaus Wilms, PhD, Martin Clemens, PhD, Wolf-Dieter Ludwig, MD, Hannes Wandt, MD, Rita Pasold, MD, Michael Unterhalt, MD

Blood (2005) 106 (11): 920.

https://doi.org/10.1182/blood.V106.11.920.920

Published: 2005

NARROW

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Clonal Evolution of Relapsed CBFB/MYH11 Rearranged Acute Myeloid Leukemia (AML)

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Costimulatory Expression Profiling of AML Blasts Identifies Surface Markers with High Correlation to Isolated NPM1 Mutation

Composition of PBMC Population and Functionality of T- and NK-Cells in AML Patients Receiving Cytotoxic Maintenance Therapy,

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy

A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only